变应性鼻炎患者特异性免疫治疗维持阶段个性化治疗方案的疗效分析  

Efficient evaluation of standardized specific immunotherapy in personalized maintenance phase to patients of allergic rhinitis

作　　者：邓玉琴[1] 杨雅琪[1] 李胜兰[1] 严彦[2] 许昱[1] 郑应红 邓爱玲[1] 陈婉仪[1] 陶泽璋[1] 

机构地区：[1]武汉大学人民医院耳鼻咽喉-头颈外科,武汉430060 [2]新加坡国立大学医学院耳鼻咽喉-头颈外科

出　　处：《临床耳鼻咽喉头颈外科杂志》2016年第4期291-294,共4页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

基　　金：国家自然基金青年项目(No:81300813);武汉大学专项科研基金(No:302274669)

摘　　要：目的:探讨特异性皮下免疫治疗(SCIT)维持阶段个性化治疗方案的疗效。方法:收集视觉模拟量表(VAS)评分以及变应性鼻-结膜炎相关的生活质量量表(RQLQ)评分,评价对症治疗组、常规SCIT组和个性化SCIT组的疗效及对变应性鼻炎患者生活质量的改善程度。采用酶联免疫吸附试验检测血清中IL-10水平。结果:治疗3年后常规SCIT组及个性化SCIT组鼻部症状以及症状整体改善程度相似,差异无统计学意义(P>0.05)。对症治疗组血清中IL-10含量分别与常规SCIT组、个性化SCIT组及健康对照组比较差异均有统计学意义(均P<0.05),而常规SCIT组与个性化SCIT组之间差异不明显(P>0.05)。结论:尘螨过敏的中-重度变应性鼻炎患者采用为期3年的常规免疫治疗和个性化免疫治疗均能获得良好效果,这两种治疗方式在改善患者生活质量方面明显优于药物对症治疗。Objective：To explore the efficacy of individualized subcutaneous immunotherapy （SCIT） in allergic rhinitis（AR） maintain phase. Method：Compare nasal symptom scores （VAS） and special disease scale- nasal con- junctivitis quality of life questionnaire（RQLQ） score after 3 years treatment to evaluate the therapeutic effect of each group and the level of improving patients quality of life. Take patients blood to detect the serum level of IL - 10 by enzyme linked immunosorbent test （enzyme linked immunosorbent assay）. Result： After 3 years treatment, there was no difference of VAS between the conventional SCIT group and the individualized SCIT group. ELISA results showed that the level of IL-10 was significantly higher in the drug symptomatic treatment group than that in the healthy group, the levels of IL-10 were significantly lower in the conventional SCIT group and the individu- alized SCIT group than that in the healthy group, but there was no difference between the conventional SCIT and the individualized SCIT group. Conclusion： After 3 years treatment, there was no difference between conventional and individualized SCIT groups. But the efficacy of the conventional and individualized SCIT groups were signifi- cantly better than that in the drug symptomatic treatment group.

关 键 词：皮下免疫治疗 鼻炎 变应性 白细胞介素10 细胞因子类 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]